{"id":258,"date":"2026-04-23T23:05:39","date_gmt":"2026-04-24T06:05:39","guid":{"rendered":"https:\/\/taurusmeds.com\/articles\/trt-prolactin-oral-approvals\/"},"modified":"2026-04-23T23:05:42","modified_gmt":"2026-04-24T06:05:42","slug":"trt-prolactin-oral-approvals","status":"publish","type":"post","link":"https:\/\/taurusmeds.com\/articles\/trt-prolactin-oral-approvals\/","title":{"rendered":"TRT and Prolactin Evidence from Oral Testosterone Approvals"},"content":{"rendered":"<style>\n  a { color: #F1471D !important; }\n  .section-spacing { margin: 2rem 0; }\n  .toc-list li { margin: 0.25rem 0; }\n<\/style>\n<h2 id=\"h-title\" class=\"wp-block-heading section-spacing\">TRT and Prolactin Evidence from Oral Testosterone Approvals<\/h2>\n<p class=\"wp-block-paragraph\"><strong>Estimated reading time:<\/strong> 8 minutes<\/p>\n<p class=\"wp-block-paragraph section-spacing\">FDA materials for Tlando note increased prolactin without consistent human data. Learn which labs to prioritize on TRT and when prolactin testing is warranted.<\/p>\n<h3 id=\"h-key-takeaways\" class=\"wp-block-heading section-spacing\">Key takeaways<\/h3>\n<ul class=\"wp-block-list\">\n<li>FDA reviewers flagged increased serum prolactin during Tlando development as an \u201cinconsistent finding,\u201d and it is not a routine monitoring requirement in final labeling.<\/li>\n<li>The prolactin signal has not been consistently observed across other TRT products, and human trial data do not quantify magnitude or frequency.<\/li>\n<li>Plausible mechanisms (e.g., HPA axis effects in animals, estradiol aromatization) remain unproven as clinically meaningful drivers in routine care.<\/li>\n<li>Prioritize standard TRT labs (testosterone, hematocrit, blood pressure, PSA). Add prolactin selectively for symptom\u2011guided scenarios.<\/li>\n<li>Open questions remain about whether oral TRT uniquely affects prolactin and what any changes mean for outcomes.<\/li>\n<\/ul>\n<h3 id=\"h-toc\" class=\"wp-block-heading section-spacing\">Table of contents<\/h3>\n<ol class=\"wp-block-list toc-list\">\n<li><a href=\"#h-why-prolactin-came-up-in-oral-trt-reviews\">Why prolactin came up in oral TRT reviews<\/a><\/li>\n<li><a href=\"#h-what-inconsistent-means\">What \u201cinconsistent\u201d really means for patients<\/a><\/li>\n<li><a href=\"#h-potential-biology\">Potential biology: why might TRT influence prolactin?<\/a><\/li>\n<li><a href=\"#h-oral-vs-injectable\">Oral vs. injectable TRT: is prolactin different?<\/a><\/li>\n<li><a href=\"#h-practical-monitoring\">Practical monitoring: what to prioritize and when to consider prolactin<\/a><\/li>\n<li><a href=\"#h-mild-bump\">How to think about a mild prolactin bump on TRT<\/a><\/li>\n<li><a href=\"#h-unknowns\">What we still don\u2019t know<\/a><\/li>\n<li><a href=\"#h-clinical-relevance\">A note on clinical relevance<\/a><\/li>\n<li><a href=\"#h-taurus-meds\">Where Taurus Meds fits<\/a><\/li>\n<li><a href=\"#h-conclusion\">Conclusion<\/a><\/li>\n<\/ol>\n<div class=\"section-spacing\">\n<h3 id=\"h-why-prolactin-came-up-in-oral-trt-reviews\" class=\"wp-block-heading\">Why prolactin came up in oral TRT reviews<\/h3>\n<p class=\"wp-block-paragraph\">Tlando, an oral testosterone undecanoate formulation (NDA 208088), underwent multiple FDA review cycles spanning several years. During those reviews, regulators highlighted several safety observations, including:<\/p>\n<ul class=\"wp-block-list\">\n<li>Increased blood pressure<\/li>\n<li>An average hematocrit rise (about 3.2% over 110 days in one key study)<\/li>\n<li>Potential HPA axis effects (evidence of adrenal cortical changes in animals)<\/li>\n<li>An inconsistent signal of increased serum prolactin<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">That \u201cinconsistent\u201d label matters. It means elevations weren\u2019t reliably demonstrated across studies or did not show clear dose-response, incidence, or clinical outcomes. Ultimately, while postmarketing monitoring was discussed across several domains, prolactin was not included as a required routine lab in the final Tlando labeling.<\/p>\n<p class=\"wp-block-paragraph\">By contrast, standard TRT warnings and monitoring remain focused on:<\/p>\n<ul class=\"wp-block-list\">\n<li>Hematocrit\/erythrocytosis<\/li>\n<li>Blood pressure<\/li>\n<li>Suppression of the pituitary\u2011testicular axis (fertility\/testicular effects)<\/li>\n<li>PSA and prostate considerations<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">Notably, prolactin does not appear as a general monitoring requirement in long\u2011standing injectable testosterone labels or in the Jatenzo (oral TU) review, underscoring that it isn\u2019t an established safety endpoint across the class.<\/p>\n<p class=\"wp-block-paragraph\">Sources: FDA summary review for Tlando; injectable testosterone label; Jatenzo medical review; FDA TRT guidance.<\/p>\n<\/div>\n<div class=\"section-spacing\">\n<h3 id=\"h-what-inconsistent-means\" class=\"wp-block-heading\">What \u201cinconsistent\u201d really means for patients<\/h3>\n<p class=\"wp-block-paragraph\">\u201cInconsistent\u201d does not necessarily mean \u201cunimportant\u201d\u2014it means the evidence is too patchy for firm regulatory conclusions. For TRT prolactin questions, the limitations include:<\/p>\n<ul class=\"wp-block-list\">\n<li>No standardized reporting of prolactin incidence or magnitude in human trials.<\/li>\n<li>Short trial durations (e.g., around 110 days for a pivotal safety dataset).<\/li>\n<li>A development focus on pharmacokinetics and blood pressure rather than prolactin.<\/li>\n<li>Lack of consistent replication across products and studies.<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">Because of these gaps, prolactin is not a routine monitoring target in product labels or in general TRT guidance. Still, individual patients may benefit from case\u2011by\u2011case testing, especially if symptoms suggest prolactin involvement.<\/p>\n<\/div>\n<div class=\"section-spacing\">\n<h3 id=\"h-potential-biology\" class=\"wp-block-heading\">Potential biology: why might TRT influence prolactin?<\/h3>\n<p class=\"wp-block-paragraph\">A few plausible pathways are discussed in regulatory and scientific contexts, none proven as a primary driver in typical TRT care:<\/p>\n<ul class=\"wp-block-list\">\n<li><strong>HPA axis interactions:<\/strong> Animal toxicology noted adrenal cortical changes at exposures relevant to testosterone therapy. Translating animal adrenal findings into human prolactin changes is speculative; the relevance in standard human dosing remains uncertain.<\/li>\n<li><strong>Aromatization to estradiol:<\/strong> Testosterone can convert to estradiol, which may influence prolactin in some contexts. If estradiol rises (for example, in patients who aromatize more readily), it might indirectly affect prolactin. Evidence connecting typical TRT dosing to clinically meaningful prolactin elevations remains limited.<\/li>\n<li><strong>Pituitary feedback:<\/strong> While injectable labels emphasize suppression of the pituitary\u2011testicular axis, routine prolactin shifts have not been established as a class effect.<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">Bottom line: theoretical mechanisms exist, but human data are thin, and clinical significance appears low for most patients.<\/p>\n<\/div>\n<div class=\"section-spacing\">\n<h3 id=\"h-oral-vs-injectable\" class=\"wp-block-heading\">Oral vs. injectable TRT: is prolactin different?<\/h3>\n<p class=\"wp-block-paragraph\">So far, the suggestion of increased prolactin has surfaced most clearly in the FDA\u2019s Tlando materials\u2014without consistent confirmation in other approvals (e.g., Jatenzo, Xyosted). That could reflect differences in study design, populations, or statistical noise rather than a true formulation effect.<\/p>\n<p class=\"wp-block-paragraph\">It remains an open question whether oral TRT uniquely affects prolactin compared with injectables or topicals. Regulatory documents do not establish a causal relationship or a consistent pattern. Without robust human data, it\u2019s prudent to view any prolactin signal as a product\u2011specific observation that has not yet generalized to the TRT category.<\/p>\n<\/div>\n<div class=\"section-spacing\">\n<h3 id=\"h-practical-monitoring\" class=\"wp-block-heading\">Practical monitoring: what to prioritize and when to consider prolactin<\/h3>\n<p class=\"wp-block-paragraph\">For most patients on TRT\u2014oral or otherwise\u2014the standard monitoring priorities remain:<\/p>\n<ul class=\"wp-block-list\">\n<li>Testosterone levels in target range per prescriber guidance<\/li>\n<li>Hematocrit\/hemoglobin to watch for erythrocytosis<\/li>\n<li>Blood pressure<\/li>\n<li>PSA and prostate assessment consistent with age and risk<\/li>\n<li>Assessment for edema, acne, mood or sleep changes, and other dose\u2011related effects<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">When to consider adding prolactin:<\/p>\n<ul class=\"wp-block-list\">\n<li>New or worsening gynecomastia not explained by other factors<\/li>\n<li>Persistent sexual dysfunction (e.g., reduced libido, anorgasmia) despite adequate testosterone exposure<\/li>\n<li>Nipple discharge or breast tenderness out of proportion to expected aromatization effects<\/li>\n<li>Refractory headaches or visual symptoms that necessitate broader endocrine evaluation<\/li>\n<li>Clinical scenarios where the prescriber already plans to check estradiol, thyroid function, or pituitary hormones and wants a fuller pituitary profile<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">This selective approach accommodates the FDA\u2019s \u201cinconsistent\u201d signal without over-testing. It also aligns with how clinicians often tailor labs to symptoms, comorbidities, and the specific formulation used.<\/p>\n<\/div>\n<div class=\"section-spacing\">\n<h3 id=\"h-mild-bump\" class=\"wp-block-heading\">How to think about a mild prolactin bump on TRT<\/h3>\n<p class=\"wp-block-paragraph\">If a prolactin elevation is found incidentally:<\/p>\n<ul class=\"wp-block-list\">\n<li><strong>Confirm it:<\/strong> Single measurements can be misleading. Non\u2011TRT factors (stress, time of day, certain medications) can affect prolactin.<\/li>\n<li><strong>Correlate with symptoms:<\/strong> Modest, asymptomatic elevations may not require immediate changes. Significant symptoms should trigger a fuller work\u2011up per clinician judgment.<\/li>\n<li><strong>Consider other labs:<\/strong> Some prescribers evaluate estradiol in symptomatic \u201chigh\u2011aromatizers,\u201d as well as thyroid function if indicated, to contextualize prolactin findings.<\/li>\n<li><strong>Revisit formulation or dose:<\/strong> If concerns persist and are plausibly linked to oral pharmacokinetics or peaks, a switch to a non\u2011oral formulation may be discussed.<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">Because the FDA materials do not quantify the prolactin signal or link it to outcomes, management remains individualized and anchored to broader clinical context rather than any single lab value.<\/p>\n<\/div>\n<div class=\"section-spacing\">\n<h3 id=\"h-unknowns\" class=\"wp-block-heading\">What we still don\u2019t know<\/h3>\n<ul class=\"wp-block-list\">\n<li>Does oral testosterone undecanoate genuinely increase prolactin more than injectable or transdermal options?<\/li>\n<li>If elevations occur, how often, how much, and at what threshold do symptoms appear?<\/li>\n<li>Are observed animal HPA findings relevant to typical human dosing and duration?<\/li>\n<li>Do estradiol levels or dose intensity explain inter\u2011individual differences?<\/li>\n<li>Will ongoing or future postmarketing studies clarify whether prolactin monitoring should be standardized for oral TRT?<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">Until these gaps close, routine prolactin testing for all TRT patients is not supported by labeling or guidance. The stronger evidence continues to support monitoring hematocrit, blood pressure, and other established safety endpoints.<\/p>\n<\/div>\n<div class=\"section-spacing\">\n<h3 id=\"h-clinical-relevance\" class=\"wp-block-heading\">A note on clinical relevance<\/h3>\n<p class=\"wp-block-paragraph\">For men on TRT, the primary concerns remain consistent: achieving physiologic testosterone exposure while minimizing risks like erythrocytosis and blood pressure changes. The current evidence suggests that clinically meaningful prolactin problems linked directly to TRT are uncommon. That said, a symptom\u2011led approach to prolactin testing can help identify rare but important issues without burdening every patient with added labs.<\/p>\n<\/div>\n<div class=\"section-spacing\">\n<h3 id=\"h-taurus-meds\" class=\"wp-block-heading\">Where Taurus Meds fits<\/h3>\n<p class=\"wp-block-paragraph\">At Taurus Meds, we track regulatory updates closely and support pragmatic, evidence\u2011based monitoring plans. If you\u2019re initiating or already on oral TRT and have symptoms that raise prolactin questions, discuss them with your prescribing clinician. Thoughtful lab selection\u2014focused on the highest\u2011value tests for your situation\u2014can keep treatment effective and safe without unnecessary complexity.<\/p>\n<\/div>\n<div class=\"section-spacing\">\n<h3 id=\"h-conclusion\" class=\"wp-block-heading\">Conclusion<\/h3>\n<p class=\"wp-block-paragraph\">TRT prolactin remains a nuanced topic. The FDA\u2019s Tlando review flagged increased serum prolactin as an inconsistent finding, and animal data raise theoretical HPA considerations. Yet no clear, reproducible human signal has prompted routine prolactin monitoring in approvals or class guidance. For now, the most practical course is to continue standard TRT monitoring and reserve prolactin testing for patients with suggestive symptoms or tailored clinical reasons\u2014especially on oral regimens\u2014while we await more definitive postmarketing data.<\/p>\n<\/div>\n<hr class=\"wp-block-separator section-spacing\" \/>\n<h3 id=\"h-disclaimer\" class=\"wp-block-heading section-spacing\">Disclaimer<\/h3>\n<p class=\"wp-block-paragraph\">This article is for informational purposes only and is not medical advice. Always consult a qualified healthcare professional about diagnosis, lab interpretation, or treatment decisions.<\/p>\n<h3 id=\"h-sources\" class=\"wp-block-heading section-spacing\">Sources<\/h3>\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/208088Orig1s000SumR.pdf\">FDA summary review for Tlando (PDF)<\/a><\/li>\n<li><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/216318s000lbl.pdf\">Jatenzo label (2022)<\/a><\/li>\n<li><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/209863Orig1s000MedR.pdf\">Jatenzo medical review (2019)<\/a><\/li>\n<li><a href=\"https:\/\/www.fda.gov\/media\/123591\/download?attachment\">FDA TRT guidance (PDF)<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>TRT and Prolactin Evidence from Oral Testosterone Approvals Estimated reading time: 8 minutes FDA materials for Tlando note increased prolactin without consistent human data. Learn which labs to prioritize on TRT and when prolactin testing is warranted. Key takeaways FDA reviewers flagged increased serum prolactin during Tlando development as an \u201cinconsistent finding,\u201d and it is [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-258","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/posts\/258","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/comments?post=258"}],"version-history":[{"count":1,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/posts\/258\/revisions"}],"predecessor-version":[{"id":259,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/posts\/258\/revisions\/259"}],"wp:attachment":[{"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/media?parent=258"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/categories?post=258"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/tags?post=258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}